Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January

Rhea-AI Summary

Kala Pharmaceuticals (NASDAQ: KALA) will participate in two investor conferences in January 2021. Mark Iwicki, Chairman and CEO, is set to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 9:10 a.m. ET. He will also have a pre-recorded fireside chat at the H.C. Wainwright BioConnect Conference, available on the Kala website starting January 11, 2021, at 6:00 a.m. ET. Kala focuses on innovative therapies for eye diseases, with products like EYSUVIS™ and INVELTYS®.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January.

Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present at the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 a.m. ET.

Additionally, Mr. Iwicki will participate in a pre-recorded fireside chat as part of the H.C. Wainwright BioConnect Conference, which will be available on the Kala website beginning Monday, January 11, 2021 at 6:00 a.m. ET.

To access the webcasts and subsequent archived recording of each presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY^® mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the October 2020 approval of EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and the January 2019 launch of INVELTYS^® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005019/en/

FAQ

When is Kala Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Kala Pharmaceuticals will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 9:10 a.m. ET.

What is the schedule for Kala Pharmaceuticals at the H.C. Wainwright BioConnect Conference?

Mark Iwicki will participate in a pre-recorded fireside chat at the H.C. Wainwright BioConnect Conference, available on the Kala website from January 11, 2021, at 6:00 a.m. ET.

What products has Kala Pharmaceuticals developed for eye diseases?

Kala Pharmaceuticals has developed EYSUVIS™ for dry eye disease and INVELTYS® for post-operative inflammation and pain following ocular surgery.

What is the focus of Kala Pharmaceuticals as a biopharmaceutical company?

Kala Pharmaceuticals focuses on the discovery, development, and commercialization of innovative therapies for diseases of the eye.